Business context and reporting period
Issuer identification: The supplied filing is Global Medical REIT Inc.’s Form 10-K, not a filing for Chiron Real Estate Inc. It covers the fiscal year ended December 31, 2017; the filing was signed March 12, 2018. Global Medical REIT is an externally managed healthcare-property REIT, with 37 facilities and approximately 1.33 million rentable square feet at year-end. Its leases are generally long-term and triple-net.
Financial and operating performance
| Metric | 2017 | 2016 |
|---|---|---|
| Total revenue | $30.3 million | $8.2 million |
| Rental revenue | $28.5 million | $8.1 million |
| Net loss | $0.1 million | $6.4 million |
| Net loss attributable to common stockholders | $1.8 million; $0.09 per share | $6.4 million; $0.68 per share |
| FFO per share | $0.41 | ($0.43) |
| AFFO per share | $0.54 | ($0.03) |
| Normalized AFFO per share | $0.56 | ($0.02) |
| Cash from operating activities | $11.6 million | ($2.7 million) |
| Cash used in investing activities | $252.7 million | $150.4 million |
| Cash from financing activities | $226.5 million | $163.6 million |
At December 31, 2017, total assets were $474.6 million, net real estate investment was $457.9 million, total debt was $203.4 million, total liabilities were $215.6 million, and total equity was $259.0 million. Cash and cash equivalents were $5.1 million, down from $19.7 million a year earlier. The weighted-average debt interest rate was 3.72%, and the reported average debt term was 2.94 years. Approximately $164.9 million of debt was floating-rate revolving-credit borrowing; $38.5 million was term and mortgage debt.
The portfolio generated approximately $35.7 million of annualized base rent at a 7.6% weighted-average capitalization rate, with 10.5 weighted-average lease years remaining. The top five tenants represented 45.5% of annualized base rent. Texas and Pennsylvania accounted for 23.6% and 16.7%, respectively. Common dividends declared were $0.80 per share for 2017; the filing says $0.67 was treated as return of capital for tax purposes. Series A preferred stock carries a 7.50% annual dividend rate on its $25 liquidation preference.
Material changes versus the prior comparable period
- Revenue rose $22.1 million, primarily as 23 acquisitions expanded the portfolio and 2016 acquisitions contributed a full year of rent. Gross real estate investment increased to $471.5 million from $206.9 million.
- Net loss narrowed to $0.1 million from $6.4 million, while loss attributable to common holders was $1.8 million after $1.7 million of preferred dividends. Expenses also increased substantially with portfolio growth, including depreciation, amortization, interest, acquisition costs, and management fees.
- Operating cash flow improved by $14.3 million to $11.6 million. Acquisition spending drove higher investing outflows; financing inflows reflected additional borrowings and common- and preferred-equity offerings.
- Debt increased to $203.4 million from $66.5 million. The company raised approximately $33.8 million net from common stock and $75.0 million net from Series A preferred stock, and expanded revolving-credit commitments during 2017.
- The company reported year-end leverage and fixed-charge coverage ratios of 0.42 and 2.27, respectively, against facility limits of 0.65 maximum leverage and 1.50 minimum coverage.
Outlook, risks, and unusual items
Management cited aging demographics, growth in healthcare spending, outpatient-care trends, and a fragmented healthcare-property market as potential supports for demand and acquisitions. It also identified market volatility and potentially less attractive acquisition capitalization rates, rising short-term interest rates, reimbursement changes, and leverage constraints as headwinds. The filing provides no formal earnings or FFO guidance.
After year-end, the company completed four acquisitions for $48.4 million at an approximately 8.6% weighted-average capitalization rate. Two additional transactions totaling $80.4 million were under purchase agreements as of March 6, 2018, subject to due diligence and closing; they were not completed acquisitions as of the filing date. On March 6, 2018, the revolving facility was increased to $340 million. The company stated that existing cash and operating cash flows should meet short-term needs other than additional acquisitions, while future growth depends on continued access to debt and equity financing.
Key risks include tenant credit and concentration, healthcare reimbursement and regulatory changes, geographic concentration, floating-rate debt without current hedging, covenant compliance, refinancing and capital-market access, and the ability to maintain REIT qualification. Approximately 80% of properties were pledged as revolving-credit collateral. A 100-basis-point increase in LIBOR was estimated to reduce annual cash flow by about $1.7 million, assuming variable-rate debt remained unchanged. The company’s base management fee is 1.5% of defined stockholders’ equity; it paid approximately $3.1 million in 2017 and no incentive fee. Management and the auditor concluded internal control over financial reporting was effective at year-end; this followed remediation of a material weakness reported for 2016. A $1.2 million first-quarter 2017 financing-cost classification error was corrected by capitalization and was assessed as not material to the previously issued quarter’s statements. The company reported no material litigation or known material environmental liability.
Important facts for investors to verify
- Confirm the issuer: the supplied document names Global Medical REIT Inc. (NYSE: GMRE), not Chiron Real Estate Inc.
- Review tenant rent coverage, significant-tenant exposure, and concentration by state and property; annualized rent is not a measure of tenant ability to pay.
- Assess debt maturities, borrowing availability under the borrowing base, covenant headroom, collateral pledges, and exposure to floating rates.
- Compare common and preferred dividend obligations with cash flow and AFFO; AFFO is a non-GAAP measure and may not be comparable across REITs.
- Check whether the two pending acquisitions closed, their funding sources, and the impact of the expanded credit facility after March 2018.
- Examine the external management agreement, related-party fees, potential termination costs, and any later decision on internalization.
- Review the audit report, control-remediation disclosures, and the corrected quarterly financing-cost classification.